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ABSTRACT: Using panels of peptides well characterized
for their ability to bind to HLA DR1, DRB1*1101, or
DRB1*0401 molecules, algorithms were deduced to pre-
dict binding to these molecules. These algorithms consist
of blocks of 8 amino acids containing an amino acid
anchor (Tyr, Phe, Trp, Leu, Ile, or Val) at position i and
different amino acid combinations at positions i12 to
i17 depending on the class II molecule. The sensitivity
(% of correctly predicted binder peptides) and specificity
(% of correctly predicted non-binder peptides) of these
algorithms, were tested against different independent
panels of peptides and compared to other algorithms
reported in the literature. Similarly, using a panel of 232
peptides able to bind to one or more HLA molecules as
well as 43 non-binder peptides, we deduced a general
motif for the prediction of binding to HLA-DR mole-
cules. The sensitivity and specificity of this general motif
was dependent on the threshold score used for the predic-
tions. For a score of 0.1, the sensitivity and specificity
were 84.7% and 69.8%, respectively. This motif was
validated against several panels of binder and non-binder
peptides reported in the literature, as well as against 35,
15-mer peptides from hepatitis C virus core protein, that
were synthesized and tested in a binding assay against a
panel of 19 HLA-DR molecules. The sensitivities and
specificities against these panels of peptides were similar
to those attained against the panels used to deduce the
algorithm. These results show that comparison of binder
and non-binder peptides, as well as correcting for the
relative abundance of amino acids in proteins, is a useful
approach to deduce performing algorithms to predict
binding to HLA molecules. Human Immunology 61,
266–278 (2000). © American Society for Histocompat-
ibility and Immunogenetics, 2000. Published by Elsevier
Science Inc.
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ABBREVIATIONS
APC antigen presenting cell
MHC major histocompatibility complex
HCV hepatitis C virus
TDh T-helper cell determinant
INTRODUCTION
Determinants recognized by T-helper cells (TDh) are
peptides of 8 to 23 amino acids (commonly 14 to 15 in
average) that are able to bind to MHC class II molecules.
TDh originate generally in endocytic cell compartments
after processing of foreign protein antigens, that have
entered the antigen presenting cell (APC) following im-
munization with an antigen or after infection, although
peptides derived from self proteins also bind to class II
molecules. Presentation of the MHC class II-peptide
complex by an APC, followed by its recognition by the
T cell receptor, leads to T cell activation. See [1] for a
thorough review on these findings.
It has been shown [2] that TDh peptides bind to a
single site in a groove of the MHC class II molecules.
Also, the association pattern of peptides to different
allele variants of murine Ia is a reflection of the MHC
restriction of the immune response [3, 4]. Several
workers have attempted to unravel the relevant struc-
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tural requirements of TDh peptides to interact with
murine [5–7] or human [8 –14] class II molecules. The
X-ray structure of a class II molecule [15] has con-
firmed that the groove is occupied by a single peptide,
and also, that its structure is similar to the one found
for class I molecules [16]. However, the binding site of
class I molecules accommodates peptides of a length of
8 to 10 amino acids [17], whereas peptides eluted from
class II molecules may vary between 8 to 23 amino
acids [18].
Because TDh play a fundamental role in the induction
of humoral [19] and cytotoxic responses [20–24] their
identification is of paramount importance. Several
groups have published algorithms for the prediction of
TDh from proteins. These algorithms are based on sev-
eral principles: (i) amino acid sequence patterns [25]; (ii)
tendency of peptides to form amphypathic alpha helices
[26]; (iii) tendency of peptides to form strip-of-helices
[27]; (iv) amino acid sequence analogies with known T
cell epitopes [7, 28]; (v) peptides eluted from M13
phages display libraries [29, 30]; (vi) elution of peptides
from HLA-DR molecules [31]; and (vii) prediction of
peptide binding by comparison with a model peptide
[32]. However, as discussed in the present publication,
these algorithms have a wide range of sensitivities and
specificities.
TDh peptides have an hydrophobic amino acid residue
near the N-terminus that plays the role of anchor for
binding to class II molecules [14, 33]. The shorter TDh
peptides are usually 9 amino acids long [34], an obser-
vation that has been confirmed by others [29, 30] when
eluting peptides from DR1, HLA DRB1*1101, and
HLA DRB1*0401 molecules expressed by filamentous
M13 phages. In all three cases the eluted peptides were
9 amino acids long. Most of these peptides contained an
hydrophobic anchor amino acid [13] (Tyr, Phe, Trp, Leu,
Ile, or Val), at the N-terminus or one residue away from
the N-terminus. Since the anchor residue could be situ-
ated at position 2, the minimal binding block might
have a length of 8 amino acids. It occurred to us that by
comparing blocks of 8 amino acids, in groups of binder
and non-binder peptides to different HLA-DR mole-
cules, algorithms could be developed for the prediction
of peptide binding to these molecules. Similarly, by
comparing blocks of peptides that were able to bind to
one or more HLA-DR molecules (DR1, DR2, DR5,
DR52a) with 43 blocks of peptides that were unable to
bind to these four HLA-DR restrictions [33], we de-
duced an algorithm for the prediction of peptide binding
to either of these molecules. These developments are
discussed in detail below and are the main aim of the
present publication.
MATERIALS AND METHODS
Peptide Synthesis
Thirty-five 15-mer peptides from hepatitis C virus core
protein genotype 1b [35] were synthesized manually by
the solid phase method of Merrifield [36] using the Fmoc
alternative [37] and a multiple solid phase peptide syn-
thesizer [38]. Peptide HA(306–320) (CPKYVKQNTL
KLATG) from Influenza A/Texas/77 virus hemaggluti-
nin was synthesized manually, and biotinylated (while
still attached to the resin) with an excess of N-hydroxy-
succinimide-conjugated biotin (NH-LC-biotin) (Pierce).
Completion of biotinylation was assessed by the ninhy-
drin test of Kaiser [39]. All peptides were at least 80%
pure as assessed by HPLC.
Cells and mAb
EBV-transformed B lymphoblastoid cell lines (EBV-
BLCL) BGE, TISI, FPAF, and MOU were obtained from
the European Collection of Animal Cell Cultures
(ECACC, PHLS, Salisbury, UK). The L243 anti-DR and
W6/32 anti-class I hybridomas were obtained from the
American Type Culture Collection (ATCC, Manasas,
VA, USA). The remaining EBV-BLCL (issued from the
Tenth Histocompatibility Workshop), the 33.1 anti-DQ
and the B7/21 anti-DP mAb were provided by Dr.
Ghislaine Sterkers. The RM3 cell line (DR-, DQ-, DP-)
derived from the human Burkitt lymphoma cell line Raji
was provided by Dr. Bernard Be´nichou. EBV-BLCL and
the RM3 cell line were grown in RPMI 1640 (Whittaker
Bioproducts) supplemented with 10% FCS (INC
Flow), penicillin and streptomycin. The 19 HLA-DR
homozygous EBV-BLCL used in the binding assay were:
JESTOM (DRB1*0101), MZ070782 (DRB1*0102),
MGAR (DRB1*1501/ DRB5*0101), BGE (DRB1*
1502/ DRB5*0102), KAS011 (DRB1*1601/ DRB5*
0201), VAVY (DRB1*0301/ DRB3*0101), RSH
(DRB1*0302/ DRB3*0101), BOLETH (DRB1*0401/
DRB4*0101), YAR (DRB1*0402/ DRB4*0101),
SWEIG (DRB1*1101/ DRB3*0202), JVM (DRB1*
1102/ DRB3*0202), TISI (DRB1*1103/ DRB3*0202),
FPAF (DRB1*1104/ DRB3*0202), CB6B (DRB1*
1301/ DRB3*0202), SLE005 (DRB1*1302/ DRB3*
0301), AMALA (DRB1*1402/ DRB3*0101), DRB1*
0101MOU (DRB1*0701/ DRB4*0101), OLGA
(DRB1*0802), DKB (DRB1*0901/ DRB4*0101).
Peptide Binding Assays
Binding assays were performed as previously described
[9, 14]. Briefly, 3.5 3 105 EBV-BLCL were co-incu-
bated during 4 hours with biotinylated HA(306-320)
(10 mM) and unbiotinilated HA(306-320) (150 mM) or
with biotinilated HA(306-320) (10 mM), and the pep-
tide to be tested (150 mM). Cells were washed twice at
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4°C with 2 ml of PBS/0.1% BSA, re-suspended in 5
mg/ml of streptavidin-fluorescein conjugate (Pierce), and
incubated at 4°C with 2 ml of PBS/0.1% BSA. Follow-
ing re-suspension in 300 ml PBS/0.1% BSA, the cell
surface fluorescence was measured by flow cytometry on
a FACScan analyzer (Becton Dickinson Immunocyto-
chemistry Systems, Mountain View, CA, USA). The
mean fluorescence of 5000 stained cells was determined.
Dead cells were excluded from the analysis by staining
with propidium iodide (1 mg/ml). Background was mea-
sured as above but in the absence of biotinylated peptide.
This value was subtracted from all measurements. All
assays were performed by triplicate. To compensate dif-
ferences in HLA-DR expression between EBV-BLCL, the
fluorescence obtained with biotinylated peptide and fluo-
resceinated streptavidin, was divided by the fluorescence
obtained after staining the corresponding EBV-BLCL
with an excess of FITC-conjugated L243 mAb (Becton
Dickinson). Specificity was demonstrated by inhibition
of binding using anti-DR, anti-DQ, anti-DP, and anti-
class I mAb (kindly provided by Dr. Ghislaine Sterkers)
by competition with unbiotinilated HA(306–320) (data
not shown).
The relative inhibitory capacity (RI%) of peptides
from HCV core protein was calculated according to the
formula:
RI% 5 100 3 (signal inhibition with peptide tested)
/ (signal inhibition with unbiotinylated HA(306–320)).
The fluorescence intensities of triplicate samples were
usually within 5% of the mean and always within 10%.
Statistical Methods
One sample Kolmogorov-Smirnov (Lilliefors) test was
used to assess normality. For variables not normally
distributed, Mann-Whitney’s U was used. For variables
normally distributed, Student’s t test for independent
samples was used. One sample proportion Z test was
used to compare amino acid relative frequencies observed
to the relative frequencies expected. x2 test was used to
measure the association between binary (6) variables.
Average Amino Acid Frequencies
Average amino acid frequencies, used throughout this
article, were calculated from the amino acid composition
of 23406 protein sequences (8224555 amino acids) from
the Swissprot data base. These frequencies were the fol-
lowing: Ala (7.8%), Cys (1.8%), Asp (5.3%), Glu
(6.3%), Phe (4.0%), Gly (7.3%), His (2.3%), Ile (5.5%),
Lys (5.9%), Leu (9.1%), Met (2.3%), Asn (4.4%), Pro
(5.1%), Gln (4.1%), Arg (5.2%), Ser (7.0%), Thr (5.8%),
Val (6.6%), Trp (1.3%), Tyr (3.2%).
Relative Abundance of Amino Acids in Binder
and Non-Binder Peptides to Different
HLA-DR Molecules
By comparing the amino acid sequences from blocks of 8
amino acids in binder and non-binder peptides to differ-
ent HLA-DR molecules, containing an anchor residue at
their N-terminal position (Tyr, Phe, Trp, Leu, Ile, or
Val), algorithms were deduced to predict peptide bind-
ing to these molecules. Thus, 77 blocks of 8 amino acids
encompassed by 43 peptides, that according to
O’Sullivan et al. [33], were unable to bind to DR1, DR2,
DR5, or DR52a, were compared with similar blocks
from 60, 52, and 52 binder peptides, eluted from DR1,
DRB1*1101, and DRB1*0401 molecules, respectively,
expressed by filamentous M13 phages [29, 30]. For the
case of DR1, besides the 43 peptides that were unable to
bind to any of the four HLA-DR tested, another 28
non-binder peptides to DR1 [33] were considered.
Comparisons between binder and non-binder blocks
were done as follows: The percentage of abundance (rel-
ative frequency) of the 20 natural amino acids at posi-
tions (i11 to i17) of blocks of 8 amino acids containing
an anchor residue at position i, was calculated both in the
population of binder and non-binder peptides (data not
shown). The frequency of abundance of these amino acids
in 23406 proteins from the Swissprot data base was also
calculated. To assess that differences in relative frequen-
cies of each amino acid at every position of the block, in
the group of binders as well as in non-binders, respect to
the reference frequencies (those obtained from the
Swissprot data base) were not due to chance alone, one
sample proportion Z values for each amino acid at each
position in binder and non-binder peptides were calcu-
lated. The frequencies of every amino acid at positions
i11 to i17 in the blocks of binders and non-binders
were then divided by the frequency of the corresponding
amino acid in the Swissprot data base. These relative
frequencies of abundance thus calculated, in conjunction
with the Z values, were used to define amino acids
having enhancing, deleterious or neutral effect on bind-
ing of peptides to HLA-DR molecules. Thus, an amino
acid was considered to have an enhancing effect, when
the ratio between its relative frequency in binders and
non-binders was equal or greater than 1.75 (75% greater
than the observed value in non-binders) and also, that its
Z value was greater than 1.28 in binders but not in
non-binders. Similarly, an amino acid was considered
deleterious when, the ratio between its relative frequency
in non-binders and binders was equal or greater than
1.75 and its Z value was lower than 21.28 in binder but
not in non-binder blocks. The Z values of 1.28 and of
21.28 are associated with a p , 0.1, which was consid-
ered as significant. Those amino acids that did not be-
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long to either of the above two groups, were considered
as having no effect on binding.
RESULTS
In order to develop algorithms for the prediction of
peptide binding to DR1, DRB1*0401 and DRB1*1101
molecules, we studied the ratios of relative abundance of
amino acids in panels of well identified binder and
non-binder peptides to these molecules. The procedure
used is specified in Methods and the algorithms thus
obtained are shown in Table 1. These ratios of relative
abundance were arbitrarily taken as positive or negative
depending on whether the amino acid had an enhancing
or deleterious effect on binding respectively. To calculate
a score representing the binding tendency of a block
containing an anchor amino acid (Y, F, W, L, I, V) at
position i, the sum of the individual contributions of
amino acids at positions i11 to i17 (the ratios between
relative frequencies shown in Table 1) was taken. A nil
value was given to those amino acids having no signifi-
cant effect on binding. In this way the scores of all
TABLE 1 Ratios of relative frequency of abundance of amino acids of binding relevancea for the prediction of
peptide binding to DR1, DRB1*0401 and DRB1*1101
DR1
Y, F, W R 5 3.06 M 5 13.85 H 5 4.30
L, I, V H 5 2.87 Q 5 3.25 L 5 2.51 M 5 10.51 M 5 1.91
Q 5 1.79 M 5 1.91 Q 5 2.48 Q 5 1.91 A 5 2.39 P 5 2.05 Q 5 1.91
i i 1 1 i 1 2 i 1 3 i 1 4 i 1 5 i 1 6 i 1 7
S 5 22.09 E 5 22.30 I 5 21.83 D 5 22.36 D 5 22.44 D 5 21.88 D 5 22.79
E 5 25.23 D 5 22.62 D 5 23.14 I 5 24.71 D 5 22.62 S 5 23.66
P 5 210.47 I 5 23.66 S 5 23.14 I 5 24.71 F 5 25.23
F 5 24.19 R 5 23.49
DRB1*0401
M 5 5.55
V 5 4.16 R 5 3.70
Y, F, W R 5 16.65 I 5 3.47 M 5 4.16 H 5 3.47
L, I, V H 5 2.43 A 5 3.93 A 5 2.77 C 5 2.50 L 5 3.19 W 5 2.77
Y 5 2.08 W 5 2.08 W 5 2.08 R 5 2.43 C 5 2.77 Q 5 2.08 L 5 1.85
i i 1 1 i 1 2 i 1 3 i 1 4 i 1 5 i 1 6 i 1 7
T 5 22.88 P 5 23.60 N 5 23.60 D 5 22.88 H 5 21.92 D 5 21.94 N 5 22.88
E 5 24.81 D 5 24.32 K 5 24.32 E 5 27.21 D 5 22.88 G 5 22.52 K 5 24.32
P 5 212.97 P 5 25.77 Q 5 22.88
Y 5 28.65
DRB1*1101
W 5 11 W 5 9.77 M 5 15.9 M 5 4.83
Y, F, W R 5 7.33 M 5 3.06 L 5 4.89 W 5 3.66 R 5 33 W 5 8.56 R 5 4.89
L, I, V G 5 3.26 Q 5 2.75 V 5 4.28 R 5 2.14 K 5 6.11 M 5 4.89 W 5 4.89
H 5 2.44 G 5 1.96 W 5 3.06 Q 5 1.83 W 5 2.44 R 5 4.58 Q 5 1.96
i i 1 1 i 1 2 i 1 3 i 1 4 i 1 5 i 1 6 i 1 7
P 5 22.29 D 5 22.45 A 5 22.45 N 5 22.36 E 5 23.27
I 5 22.45 D 5 23.27 A 5 22.45 T 5 24.91
E 5 24.09 V 5 22.45 D 5 25.73
L 5 23.27
S 5 23.27
T 5 25.73
E 5 210.6
a See text for a detailed explanation on the calculation of the relative frequency of abundance for each amino acid at all positions. Basically, the frequency of
abundance of an amino acid at a given position is the ratio between the frequency of abundance of the amino acid at this position in binder peptides (fbp), respect
to the frequency in non binder peptides at the same position (fnbp). When the amino acid has an enhancing effect on binding, the ratio fbp/fnbp is taken as positive
whereas if the amino acid has a deleterious effect on binding, the ratio fnbp/fbp is arbitrarily taken as negative. All binder peptides must have an anchor residue:
Tyr, Phe, Trp, Leu, Ile, or Val at position i. Positive and negative values correspond to enhancing and deleterious amino acids respectively. A nil value is given
to those amino acids having no effect on binding (not shown). The score is calculated by adding the individual contributions of amino acids at positions i 1 1
to i 1 7.
The score of peptide YRELDAQH according to the DR1 motif would be:
Score 5 7.6 5 (3.06)1(22.3)1(2.51)122.36)1(2.39)1(0)1(4.30)
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potential blocks contained by the peptides screened were
calculated (see legend to Table 1 for a calculation exam-
ple).
As shown below, in order to validate the three algo-
rithms from Table 1, we tested their sensitivity and
specificity against different panels of well identified
binder and non-binder peptides reported by several re-
search groups. We have defined the sensitivity and spec-
ificity of the predictions as the percentage of correctly
predicted binder and non-binder peptides, respectively.
We also tested these algorithms against 35, 15-mer
synthetic peptides from HCV core protein whose bind-
ing ability to 19 HLA-DR molecules was measured by
flow cytometry (Fig. 1). Moreover, using the same panels
of peptides, the sensitivities and specificities of these
algorithms were compared with those attained with
other algorithms reported in the literature [32, 40–42].
In Table 2, we compare the predictions made with the
DR1 algorithm, deduced in the present publication,
with another algorithm reported by Southwood et al.
[42], which we adapted to predict binding using 8
amino acid blocks instead of 9 amino acid blocks re-
ported by these authors. Calculations were carried out
using the amino acid parameter values indicated in Fig.
2 of their publication but using only the first 8 amino
acids. In Table 2, we compare the sensitivities and spec-
ificities of our algorithm with those attained with the
modified algorithm of Southwood et al. [42]. For a given
specificity, the sensitivity of our algorithm was higher
than that attained with the modified algorithm of South-
wood et al. [42], both against the set of 94 binder
peptides to DR1, as well as to another set of 30 peptides
that bind to DRB1*0101/0102 (taken from Prof. Ram-
mensee data base published at web page: http://www.
uni-tuebingen.de/uni/kxi) (Table 2). However, both al-
gorithms behave similarly when tested against binder
and non-binder peptides to DRB1*0101 from HCV core
protein (Table 2).
In Table 3 we compare the predictions made with the
algorithm DRB1*0401 deduced in the present publica-
FIGURE 1 Relative binding capacity of 35 peptides from
HCV core protein to 19 different HLA-DR molecules as
studied by flow cytometry. This was calculated by the inhibi-
tion of the binding of biotinylated peptide HA(306-320) to
HLA-DR molecules in competition experiments. The relative
inhibitory capacity (RI%) of peptides was calculated according
to the Formula:
RI% 5 1003 (signal inhibition with peptide tested)/(signal
inhibition with unbiotinylated HA(306-320)).
The fluorescence intensities of triplicate samples were usually
within 5% of the mean and always within 10%. See Methods
for a detailed explanation of the calculation of RI%. A plus
sign indicates that at a score $ 0.1, the peptide is predicted as
binder by the DRGen algorithm.
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tion, with another four algorithms reported by others
[32, 40–42], three of which were adapted to predict
binding using the parameter values indicated by these
authors, but the length was restricted to 8 amino acid
blocks. Three panels of binder and non-binder peptides
were used to compare these algorithms. The first panel
contains some of the peptides used to deduce the
DRB1*0401 algorithm of the present publication, the
second panel corresponds to 27 binder and 41 non-binder
peptides reported by Honeyman et al. [41], and the third
panel corresponds to peptides from HCV core protein
tested in the present publication (see data from Fig. 1).
With respect to the data of Honeyman et al. [41], we
considered the peptides as binder when they behave as
such in their binding assay or in their biological assay,
the remaining were considered as non-binders. With the
exception of the algorithm of Honeyman et al. [41],
which had a higher sensitivity and specificity for the
prediction of their peptides, the algorithm DRB1*0401
developed in the present publication compares favorably
with the other algorithms from Table 3 when tested
against panel 1 and panel 2 of peptides. However, when
these algorithms were tested against panel 3 (peptides
from HCV core protein, the modified algorithm from
Southwood et al. [42] was found to be more specific for
a given sensitivity (Table 3).
Because, as shown in Fig. 1, some peptides may bind
to different HLA-DR molecules, we decided to investi-
gate the cross predictivity of each algorithm by testing it
against peptides of their own restriction as well as against
peptides of the other two restrictions. As shown in Table
4, all three algorithms predicted peptide binding to their
corresponding HLA-DR molecule with higher sensitiv-
ity. However, an important crossprediction for the other
restrictions was observed. Theses results suggested to us
to develop an algorithm for the degenerate prediction to
several HLA-DR restrictions. As for the algorithms re-
ported here, this general algorithm was deduced by
comparing blocks of binder peptides with blocks of
non-binder peptides. Thus, we compared blocks of
binder peptides to DR1 (60 peptides [29]), DRB1*1101
(52 peptides [30]), DRB1*0401 (52 peptides [30]),
DR1, DR2, DR5, DR52a (63 peptides [33]), and 47
peptides binding to a variety of HLA-DR molecules
[9–12, 14, 31, 33, 43–55] with 43 peptides that were
unable to bind to DR1, DR2, DR5 or DR52a [33]. This
afforded the algorithm DRGen shown in Table 5.
To validate the DRGen algorithm we tested it against
several panels of well characterized binder and non-
binder peptides as well as against the 35, 15-mer pep-
tides from hepatitis C virus core protein genotype 1b
from Fig. 1. As shown in Fig. 1 and Table 6, the DRGen
motif predicts the binding of core peptides to the panel
of 19 HLA-DR molecules with a sensitivity of 75.9%
and a specificity of 69.8% when the score was ˜0.1. If a
score ˜2.0 was selected the sensitivity decreased to
62.1% but the specificity increased to 76.7%. We also
validated our algorithm against several panels of peptides
that have been reported to bind to a wide range of
HLA-DR molecules (see Table 6). As shown in Table 6,
TABLE 2 Sensitivity (%) and specificity (%) of two algorithms to predict binding of peptides to DR1. Effect of
score on the sensitivity and specificity of the predictions
Algorithm Score
Sensitivity
against 94
BPa to
DR1
Sensitivity
against 30 BPb
to DRB1*0101
Specificity
against 71
NBPc to
DR1
Sensitivity
against 8 BPd
to DRB1*0101
Specificity
against 27
NBPe to
DRB1*0101
DR1 $0.1 77.7 80.0 71.8 75 74.1
(this work) $2.0 75.5 73.3 81.7 75 74.1
$5.0 53.2 43.3 90.1 25 92.6
DRB1*0101f $0.01 68.1 73.3 32.4 100 59.2
(Southwood et al.) $0.183g 63.8 73.3 56.3 100 70.4
$1.57h 52.1 66.7 71.8 62.5 85.5
BP 5 binder peptides, NBP 5 non-binder peptides.
a 60 peptides from [29] plus 34 peptides from [33].
b 30 binder peptides from Prof. Rammensee web page: http//www.uni-tuebingen.de/uni/kxi.
c 71 non-binder peptides from [33] that had at least one core of 8 amino acids binding with an anchor residue at their N-terminus and that were used in the present
work to deduce the algorighm to predict binding to DR1.
d 8 binder peptides to DRB1*0101 from HCV core protein (this work, see Fig. 1).
e 27 non-binder peptides to DRB1*0101 from HCV core protein (this work, see Fig. 1).
f Adapted from [42] to predict binding using peptide blocks of 8 amino acids.
g According to [42] threshold for prediction of 90% of the binders in their peptide library.
h According to [42] threshold for prediction of 75% of the binders in their peptide library.
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the sensitivity of the predictions against these panels is
similar to that attained against panel 1 used to develop
the algorithm. However, the specificity against panels 6
and 7 of non-binder peptides was lower than that at-
tained against the non-binder peptides from panel 8 that
was used to develop the algorithm.
DISCUSSION
By comparing blocks of peptides of 8 amino acids found
in binder and non-binder peptides to different HLA-DR
molecules, several algorithms were deduced to predict
peptide binding to these molecules. As shown in Tables
2 and 3, when these algorithms were tested against
several panels of peptides, it was found that they were in
most cases able to predict binding of peptides to
HLA-DR molecules with similar or higher sensitivity
and specificity than other reported algorithms [32, 40,
42]. This was found, not only when the comparison was
made against panels of peptides used to develop our
algorithms, but most important, when independent pan-
els of peptides were used. We believe that a key step in
the deduction of our algorithms is the use of binder and
non-binder peptides as well as correcting for the relative
abundance of amino acids in proteins.
Since our algorithms are based on blocks of 8 amino
acids, but the algorithm of Southwood et al. [42], of
Hammer et al. [40], and of Marshall et al. [32] use 9, 9,
and 11 amino acid blocks, respectively, we adapted their
algorithms to the prediction using 8 amino acid blocks.
This was done because when their algorithms were tested
using blocks of 9 or 11 amino acids like in their original
algorithm, the sensitivity of the predictions against the
9-mer peptides eluted from DR1 [29], DRB1*1101, and
DRB1*0401 [30], was lower than the one attained using
blocks of 8 amino acids (data not shown). Indeed, none of
TABLE 3 Comparison of different algorithms for the prediction of binding to DRB1*0401 class II molecules
on three panels of binder and non binder peptides. Effect of score on the percentage of sensitivity and
percentage of specificity of the predictions
Algorithm
Score or
IC50
Panel 1 Panel 2 Panel 3
BPa NBPb BPc NBPd BPe NBPf
Sensi Speci Sensi Speci Sensi Speci
Sco $ 0.1 90.0 67.4 100 48.8 75.0 37.0
DRB1*0401 Sco $ 2.0 88.7 76.7 96.3 53.6 50.0 51.8
(this paper) Sco $ 5.0 73.7 86.0 70.4 75.6 12.5 70.4
Honeyman et al.g Score $ 6.0 NT NT 74.1 85.4 NT Nt
DRB1*0401 Sco $ 0.0 90.0 51.2 92.6 46.3 75.0 44.4
Adapted from Sco $ 2.0 80.0 83.7 55.5 90.2 12.5 88.9
Hammer et al.h Sco $ 5.0 21.2 97.7 7.4 100 0 100
Sco $ 0.250 76.2 48.8 74.1 53.7 75.0 85.2
DRB1*0401 Sco $ 0.734j 62.5 69.8 66.7 68.3 50.0 88.9
(Southwood et al.i) Sco $ 2.617k 41.2 83.7 44.4 92.7 25.0 96.3
DRB1*0401 IC50 # 5000 93.7 13.9 100 14.6 75.0 48.1
Adapted from IC50 # 73.5 76.2 69.8 66.7 70.7 37.5 88.9
Marshall et al.l IC50 # 14.7 52.5 81.4 44.4 100 25.0 96.3
BP 5 binder peptides; NBP 5 non-binder peptides; Sensi 5 sensitivity; Speci 5 specificity.
a 52 binder peptides from [29] plus 28 binder peptides from [32].
b 43 non-binder peptides from [33] that do not bind to DR1, DR2, DR5, or DR52a.
c 27 binder peptides from [41].
d 41 non-binder peptides from [41].
e 8 binder peptides to DRB1*0401 from HCV core protein (this paper, see Fig. 1).
f 27 non binder peptides to DRB1*0401 from HCV core protein (this paper, see Fig. 1).
g Algorithm of Honeyman et al. [41].
h Algorithm adapted from [40] to predict binding using blocks of 8 amino acids.
i Algorithm adapted from [42] to predict binding using blocks of 8 amino acids.
j According to [42] threshold for prediction of 90% of the binders in their peptide library.
k According to [42] threshold for prediction of 75% of the binders in their peptide library.
l Algorithm adapted from [32] to predict binding using blocks of 8 amino acids.
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the 9 amino acid peptides reported by Hammer et al.
would have been predicted by the original algorithm of
Marshall et al. [32] that requires 11 amino acids for the
predictions. Moreover, for the panels of peptides tested,
the adapted algorithms shown in the present publication
have a higher sensitivity of prediction than the unmod-
ified algorithms. Thus, we believe that these adaptations
are not detrimental respect to the original algorithms.
As shown in Tables 2 through 4 the sensitivities and
specificities of the different algorithms were dependent
on the threshold scores used in the predictions. At high
scores the algorithms became more specific (higher per-
TABLE 4 Sensitivity and specificity of different algorithms to predict binding of peptides to their
corresponding MHC restriction as well as to other MHC restrictions. Effect of score on the sensitivity
and specificity of the prediction using 8 amino acid blocks with an anchor residue at their
N-terminus.
Algorithm
Score or
IC50
Predicted sensitivity and specificity of binding (%)
Sensi against
94 BPa to
DR1
Sensi against
52 BPb to
DRB1*1101
Sensi against
80 BPc to
DRB1*0401
Overall Sensi
against 226
BPPd
Speci against
NBPe
Sensi against
BPf
(this work)
Speci against
NBPf
(this work)
DR1
Score $ 0.1 77.7 59.6 67.5 69.9 71.8 52.9 72.2
Score $ 2.0 75.5 51.9 55.0 62.8 81.7 47.1 72.2
Score $ 5.0 53.2 36.5 21.2 38.0 90.1 17.6 94.4
DRB1*1101
Score $ 10 51.1 78.8 18.7 46.0 82.5 50.0 80.9
Score $ 15 34.0 75.0 12.5 35.8 90.0 35.7 80.9
Score $ 40 3.2 44.2 0 11.5 97.5 14.3 90.5
DRB1*0401
Score $ 0.1 77.6 71.1 90.0 80.5 67.4 75.0 37.0
Score $ 2.0 68.1 69.2 88.7 75.7 76.7 50.0 51.8
Score $ 5.0 48.9 38.5 73.7 55.3 86.0 12.5 70.4
BP 5 binder peptides, NBP 5 non-binder peptides, Sensi 5 sensitivity, Speci 5 specificity.
a94 BP to DR1 (60 peptides from [29] plus 34 peptides from [33]).
b52 BP to DRB1*1101 from [30].
c80 BP to DRB1*0401 (52 peptides from [30] plus 28 peptides from [32]).
d226 peptides from DRB1*0401, DRB1*1101 and DR1a, b, c, respectively.
eThese specificities of binding were calculated against the following sets of NBP:
for DR1: 71 NBP to DR1 reported by [33] and having an anchor at their N-terminus.
for DRB1*1101: 80 NBP to DR5 reported by [33] and having an anchor at their N-terminus.
for DRB1*0401: 43 NBP to DR1, DR2, DR5 or DR52a reported by [33] and having an anchor at their N-terminus.
fThese sensitivities and specificites of binding were calculated using BP and NBP from Fig. 1:
for DR1 (17 peptides binding to DRB1*0101 or to DRB1*0102 or to both, as well as 18 peptides that did not bind to any of these two restrictions).
for DRB1*0101 (14 BP and 27 NBP from HCV core protein, see Fig. 1).
for DRB1*0401 (8 BP and 27 NBP from HCV core protein, see Fig. 1).
TABLE 5 DRGen binding motif. Ratios of relative frequency of abundance of amino acids of binding relevancea
A 5 2.78 H 5 3.45
Y,F,W R 5 8.76 W 5 2.15 M 5 7.61 V 5 3.09
L,I,V W 5 2.23 R 5 2.06 L 5 3.06 R 5 1.94 R 5 9.19 R 5 2.83
Y 5 1.72 K 5 2.01 A 5 1.80 M 5 1.87 K 5 2.94 R 5 1.83 W 5 1.72
i i 1 1 i 1 2 i 1 3 i 1 4 i 1 5 i 1 6 i 1 7
C 5 25.22 P 5 21.93 D 5 22.05 P 5 21.74 E 5 24.31 S 5 21.80 S 5 22.51
P 5 27.83 D 5 22.98 T 5 22.32 E 5 21.83 H 5 24.35 D 5 24.06 F 5 22.78
E 5 23.31 E 5 22.61 D 5 21.86 D 5 23.80
C 5 22.78
aSee text for a detailed explanation on the calculation of the relative frequency of abundance for each amino acid at all positions. Basically, the frequency of
abundance of an amino acid at a given position is the ratio between the frequency of abundance of the amino acid at this position in binder peptides (fbp), respect
to the frequency in nonbinder peptides at the same position (fnbp). When the amino acid has an enhancing effect on binding, the ratio fbp/fnbp is taken as positive
whereas if the amino acid has a deleterious effect on binding, the ratio fnbp/fbp is arbitrarily taken as negative. All binder peptides must have an anchor residue:
Tyr, Phe, Trp, Leu, Ile, or Val at position i. Positive and negative values correspond to enhancing and deleterious amino acids, respectively. A nil value is given
to those amino acids having no effect on binding (not shown). The score is calculated by adding the individual contributions of amino acids at positions i11 to
i17. The score of peptide FRGDRKSH would be: Score 5 13.24 5 (8.76)1(0)2(2.05)1(1.94)1(2.94)2(1.80)1(3.45) for a block of 8 amino acids.
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centage of correctly predicted non-binder peptides) but
at the expense of an important drop in sensitivity (lower
percentage of correctly predicted binder peptides). Thus,
the choice of the threshold level will depend on the
viability of experimentally testing the binding of the
peptides to MHC molecules or their TDh character.
As shown in Fig. 1 as well as in data reported in the
literature [12, 56] some peptides are able to bind to
different class II molecules, showing degeneracy in bind-
ing. For this reason, we decided to study the level of
crosspredictivity of our algorithms. As shown in Table 4
when the algorithms for DR1, DRB1*1101, and
DRB1*0401 were tested, it was found that although
each algorithm was more sensitive against peptides of its
own restriction, a great deal of cross prediction was
observed. The algorithm with less cross prediction was
the one for DRB1*1101, which at scores ˜ 40, when
tested against peptides known to bind to DRB1*1101
and against two other panels known to bind to DR1 or
to DRB1*0401, predicted binding with sensitivities of
44.2%, 3.2%, and 0%, respectively. This low crosspre-
diction may be related to the superior specificity of this
algorithm. Indeed, for scores ˜ 40, 78 of the 80 peptides
that did not bind to DR5 [33] were predicted as non-
binder, which corresponds to a specificity of 97.5%.
(DR5 is an alternative nomenclature for DR11.) This
type of crossrecognition has been reported for other
HLA-DR molecules. Thus, based on the sequence of
eluted peptides from DR2, DR3, DR4, DR7, and DR8,
Chicz et al. [31] proposed DR-specific peptide motifs.
However, the motif described for a given DR restriction
can also be found in peptides eluted from other DR
molecules (Table 8 from Chicz et al. [31]). Thus, the
sequence alignment for DR2 suggested by Chicz et al. is
also fulfilled by 23.6% of peptides eluted from the
remaining four other DR molecules. Similarly, the se-
quence alignments for DR3, DR4, DR7, and DR8 are
fulfilled by 57.2%, 27.3%, 59.7%, and 32.7% of pep-
tides eluted from the remaining DR molecules respec-
tively (data not shown). This shows that eluted peptides
may contain more than one DR specificity.
The observation that the same peptide could be pre-
dicted by algorithms for different HLA-DR restrictions,
as well as the results from Chicz et al. [31] discussed
above, prompted us to develop a motif for the degenerate
prediction of binding to several HLA-DR restrictions. It
was also thought that this motif might be a useful tool
in vaccine development for the selection of those regions
of an antigen with the capacity of binding to several
HLA-DR restrictions. Thus, as described earlier, we de-
duced the algorithm DRGen shown in Table 5. This
algorithm was then validated using several panels of
peptides characterized by others [31, 33, 41], (Prof.
Rammensee), as well as against 35 peptides from HCV
core protein tested in the present study (Fig. 1). This
validation showed similar sensitivities and specificities
than those attained using the panels of peptides used to
develop the DRGen algorithm (Table 6). These results
suggest that the DRGen algorithm may be a useful tool
to predict binding to HLA-DR molecules.
As shown in Fig. 1, 22/29 (75.9%) of binder peptides
from hepatitis C virus core protein genotype 1b were
predicted as such by the DRGen algorithm. It is inter-
esting to note that none of the peptides, which were able
to bind to several HLA-DR molecules, was left unpre-
dicted. Indeed, peptides that were not predicted were
either non-binder or peptides that bound to few of the 19
HLA-DR molecules tested. These results show that those
peptides that are able to bind to many HLA-DR mole-
cules are efficiently predicted by the DRGen motif. Of
the 6 non-binder peptides 4 were predicted as non-
binder but the other 3 were predicted as binder.
Other researchers [25, 26] have published algorithms
for the prediction of binding to MHC class II molecules.
When we tested their algorithms using the program “T
sites” [57] it was found that for a given specificity the
sensitivity of these algorithms was well below that at-
tained by the DRGen algorithm (data not shown).
In Table 7 we compare the role of amino acids on
binding of peptides to HLA-DR molecules reported by
others [33, 34, 44, 54, 58–61] with that of the general
DRGen binding motif. This shows that most of the
TABLE 6 Validation of the algorithm DRGen
against different panels of binder and
non-binder peptides. Effect of score on
the sensitivity and specificity of the
predictions
Score
Sensitivity (%) Specificity (%)
1a 2b 3c 4d 5e 6f 7g 8h
Score $ 0.1 84.7 84.4 81.5 87.3 75.9 51.2 66.7 69.8
Score $ 2.0 81.4 76.7 66.7 78.8 62.1 58.5 66.7 76.7
Panel 1 and panel 8, in bold, and panel 2 to panel 7 were used to develop and
validate the algorithm, respectively.
aPanel of 232 BP from [33] and others (see text from results section).
bPanel of 90 BP from [31] eluted from different HLA-DR molecules (1, 11,
16, 11, 18, and 33 peptides eluted from DR1, DR2, DR3, DR4, DR7, and
DR8, respectively).
cPanel of 27 BP from [41].
dPanel of 165 BP from Prof. Rammensee web page: http://www.uni-
tuebingen. de/uni/kxi (37, 13, 12, 18, 25, 7, 8, 4, 8, 15, 15, 3 peptides from:
HLA-DRB1*0301, HLA-DRB1*0901, HLA-DRB1*1201, HLA-
DRB1*1301, HLA-DRB1*1302, HLA-DRB1*1401, HLA-DRB1*1501,
HLA-DRB1*1502, HLA-DR3, HLA-DRB5*0101, HLA-DR2 (DRB5*0101
or DRB1*1501, and HLA-DR7) respectively.
ePanel of 29 BP from HCV core protein from the present study (see Fig. 1).
fPanel of 41 NBP from [41].
gPanel of 6 NBP from HCV core protein from the present study (see Fig. 1).
hPanel of 43 NBP from [33].
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effects reported are compatible with our peptide binding
motif. It is clear that, in addition to an anchor residue,
binder peptides should have few, if any, amino acids
giving negative interactions with the MHC. It has been
suggested that the absence of “negative” amino acids may
be more important than the presence of amino acids
giving a “positive” interaction with MHC [58]. Also, the
reported enhanced binding of peptide HEL(104–120) at
acidic pH [59], where the net charge is less negative, is
in agreement with the disrupting effect on binding of
Asp and Glu at several positions of the peptide at higher
pH [60] where the net charge is more negative.
The crystal structure of an HLA-DR1 molecule com-
plexed with peptide HA(306-318) shows that residues
Tyr308, Gln311, Thr313, Leu314, and Leu316 of
HA(306-318) interact respectively with pockets 1, 4, 6,
7, and 9 of the HLA-DR1 molecule (See Fig. 4 from
publication of Stern et al. [62]). If we consider that
Tyr308 corresponds to the anchor at position i of our
peptide motif, then pockets 1, 4, 6, 7 and 9 of the MHC
may interact with positions i, i13, i15, i16, and i18
of the motif, respectively. Thus, the enhancing or dis-
rupting effect of amino acids at positions i13, i15, i16,
and i18 of the motif should be compatible with the
amino acids delimiting pockets 4, 6, 7, and 9 of the
MHC, respectively. Thus, pocket 1 is formed mainly by
hydrophobic residues [62]. This is compatible with the
interaction with the reported hydrophobic anchor :Tyr,
Phe, Trp, Leu, Ile, Val at position i.
Pocket 4 may interact with residue i13 of the DRGen
motif which favours Met and Leu at this position. This
preference may be related with packing of Met or Leu
with the hydrophobic residues Phe/His/Tyrb13 (of some
DR molecules) and Tyrb78 in the pocket. The deleteri-
ous effect of Asp and Glu may be related with an elec-
trostatic repulsion against a negatively charged amino
acid close to pocket 4, like Glub28 in DR1, and Aspb28
in the remaining DR molecules.
Positions i15, i16, and i18, which interact with
pockets 6, 7 and 9 of the MHC molecule, do not favor
Asp residues (Table 5) suggesting the presence of nega-
tively charged residues at/or near these MHC pockets.
For instance Glu a11 and Asp a66 from pocket 6 and
Asp b57 from pocket 9 and/or with Glu b9 in most DR
molecules. The presence of these negatively charged res-
idues of the MHC molecule, might also explain the
enhancing effect on binding of Arg in those positions
where the negatively charged residues have a deleterious
effect. Thus, the general amino acid topology of the
binder peptide DRGen motif favors hydrophobic and
positively charged amino acids, which have chemical
affinity for hydrophobic and negatively charged amino
acids respectively (Table 8). Also, the strong deleterious
effect due to Pro, at position i11 may be related to the
reported effect on the orientation of the peptide chain by
Pro [63, 64] that may prevent the amino acids from the
peptide to interact with the HLA-DR molecule.
To summarize, the published HLA-DR structure [62]
suggests that its general topology may be complemen-
tary to the topology associated with the proposed
DRGen peptide binding motif. This motif is able to
predict with high sensitivity and specificity those regions
of an antigen that may bind to HLA-DR molecules. This
prediction, in conjunction with a better understanding of
antigen processing and of immunodominancy, due to
higher affinity of peptides for HLA-DR molecules and/or
higher affinity of the complex: peptide-(class II mole-
cule) by the T cell receptor, may allow in not too distant
future, the identification of the most relevant TDh from
antigens. This is of paramount importance because TDh
are essential for the induction of humoral and cellular
TABLE 7 Effect of amino acids at positions i to i17 on binding of peptides to MHC class II molecules
i i 1 1 i12 i13 i14 i15 i16 i17 Ref
Y1F1W1 K1R1 K1R1 [54]
Y1F1W1 K1R1 [34]
Absense of negative interactions at all positions, more important than presence of positive interactions [58]
Enhanced binding of peptide HEL (104-120) at acidic pH [59]
E2 E2 [44]
Y1 D2 D2 D2 D2 D2 D2 [60]
E2 [12]
E2 [61]
Y,F,W,I,L,V R1W1Y1 A1K1R1W1 A1L1M1 M1R1 K1R1 R1 H1R1V1W1 This
anchor C2P2 D2E2P2 C2D2E2T2 D2E2P2 E2H2 D2S2 D2F2S2 work
1Enhancing effect on binding.
2Deleterious effect on binding.
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immune responses, and consequently, for the design of
future vaccines.
ACKNOWLEDGMENTS
This work was partly supported by grants from the Departa-
mento de Salud, Gobierno de Navarra, Project: No 840, by
C.I.C.Y.T project: SAF97-0223, and from AIRTEL 97.
REFERENCES
1. Germain RN, Margulies DH: The biochemistry and cell
biology of antigen processing and presentation. Annu Rev
Immunol 11:403, 1993.
2. Guillet JG, Lai MZ, Briner TJ, Smith JA, Gefter ML:
Interaction of peptide antigens and class II major histo-
compatibility complex antigens. Nature 324(6094):260,
1986.
3. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue
ER: Binding of immunogenic peptides to Ia histocompat-
ibility molecules. Nature 317(6035):359, 1985.
4. Buus S, Sette A, Colon SM, Miles C, Grey HM: The
relation between major histocompatibility complex
(MHC) restriction and the capacity of Ia to bind immu-
nogenic peptides. Science 235(4794):1353, 1987.
5. Sette A, Buus S, Colon S, Smith JA, Miles C, Grey HM:
Structural characteristics of an antigen required for its
interaction with Ia and recognition by T cells. Nature
328(6129):395, 1987.
6. Sette A, Adorini L, Appella E, Colon SM, Miles C, Tanaka
S, Ehrhardt C, Doria G, Nagy ZA, Buus S, et al.: Struc-
tural requirements for the interaction between peptide
antigens and I-Ed molecules. J Immunol 143(10):3289,
1989.
7. Sette A, Buus S, Appella E, Smith JA, Chesnut R, Miles
C, Colon SM, Grey HM: Prediction of major histocom-
patibility complex binding regions of protein antigens by
sequence pattern analysis. Proc Natl Acad Sci USA 86(9):
3296, 1989.
8. Busch R, Rothbard JB: Detection of peptide-MHC class II
complexes on the surface of intact cells. J Immunol Meth-
ods 134(1):1, 1990.
9. Busch R, Strang G, Howland K, Rothbard JB: Degenerate
binding of immunogenic peptides to HLA-DR proteins
on B cell surfaces. Int Immunol 2(5):443, 1990.
10. Jardetzky TS, Gorga JC, Busch R, Rothbard J, Strominger
JL, Wiley DC: Peptide binding to HLA-DR1: a peptide
with most residues substituted to alanine retains MHC
binding. Embo J 9(6):1797, 1990.
11. Roche PA, Cresswell P: High-affinity binding of an in-
fluenza hemagglutinin-derived peptide to purified HLA-
DR. J Immunol 144(5):1849, 1990.
12. O’Sullivan D, Arrhenius T, Sidney J, Del Guercio MF,
Albertson M, Wall M, Oseroff C, Southwood S, Colon
SM, Gaeta FC, Sette A: On the interaction of promiscuous
antigenic peptides with different DR alleles. Identifica-
tion of common structural motifs. J Immunol 147(8):
2663, 1991.
13. Krieger JI, Karr RW, Grey HM, Yu WY, O’Sullivan D,
Batovsky L, Zheng ZL, Colon SM, Gaeta FC, Sidney J,
Albertson M, Del Guercio MF, Chesnut RW, Sette A:
Single amino acid changes in DR and antigen define
residues critical for peptide-MHC binding and T cell
recognition. J Immunol 146(7):2331, 1991.
14. Hill CM, Hayball JD, Allison AA, Rothbard JB: Confor-
mational and structural characteristics of peptides binding
to HLA-DR molecules. J Immunol 147(1):189, 1991.
15. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG,
Strominger JL, Wiley DC: Three-dimensional structure of
the human class II histocompatibility antigen HLA-DR1
[see comments]. Nature 364(6432):33, 1993.
16. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS,
Strominger JL, Wiley DC: Structure of the human class I
histocompatibility antigen, HLA-A2. Nature 329(6139):
506, 1987.
17. Matsumura M, Fremont DH, Peterson PA, Wilson IA:
Emerging principles for the recognition of peptide anti-
gens by MHC class I molecules [see comments]. Science
257(5072):927, 1992.
18. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ,
Vignali DA, Strominger JL: Predominant naturally pro-
cessed peptides bound to HLA-DR1 are derived from
MHC-related molecules and are heterogeneous in size.
Nature 358(6389):764, 1992.
19. Milich DR: Synthetic T and B cell recognition sites:
implications for vaccine development. Adv Immunol 45:
195, 1989.
20. Keene JA, Forman J: Helper activity is required for the in
vivo generation of cytotoxic T lymphocytes. J Exp Med
155(3):768, 1982.
21. Leist TP, Cobbold SP, Waldmann H, Aguet M, Zinker-
nagel RM: Functional analysis of T lymphocyte subsets in
antiviral host defense. J Immunol 138(7):2278, 1987.
22. Fayolle C, Deriaud E, Leclerc C: In vivo induction of
cytotoxic T cell response by a free synthetic peptide re-
quires CD41 T cell help. J Immunol 147(12):4069,
1991.
23. Lasarte JJ, Sarobe P, Gullon A, Prieto J, Borras Cuesta F:
Induction of cytotoxic T lymphocytes in mice against the
principal neutralizing domain of HIV-1 by immunization
with an engineered T-cytotoxic-T-helper synthetic pep-
tide construct. Cell Immunol 141(1):211, 1992.
24. Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman
M, Berzofsky JA: Helper-cytotoxic T lymphocyte (CTL)
determinant linkage required for priming of anti-HIV
CD81 CTL in vivo with peptide vaccine constructs. J Im-
munol 152(2):549, 1994.
25. Rothbard JB, Taylor WR: A sequence pattern common to
T cell epitopes. EMBO J 7(1):93, 1988.
26. Margalit H, Spouge JL, Cornette JL, Cease KB, Delisi C,
Berzofsky JA: Prediction of immunodominant helper T
276 F. Borra´s-Cuesta et al.
cell antigenic sites from the primary sequence. J Immunol
138(7):2213, 1987.
27. Stille CJ, Thomas LJ, Reyes VE, Humphreys RE: Hydro-
phobic strip-of-helix algorithm for selection of T cell-
presented peptides. Mol Immunol 24(10):1021, 1987.
28. Guillet JG, Hoebeke J, Lengagne R, Tate K, Borras-
Herrera F, Strosberg AD, Borras-Cuesta F: Haplotype
specific homology scanning algorithm to predict T-cell
epitopes from protein sequences. J Mol Recognit 4(1):17,
1991.
29. Hammer J, Takacs B, Sinigaglia F: Identification of a
motif for HLA-DR1 binding peptides using M13 display
libraries. J Exp Med 176(4):1007, 1992.
30. Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J,
Takacs B, Sinigaglia F: Promiscuous and allele-specific
anchors in HLA-DR-binding peptides. Cell 74(1):197,
1993.
31. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS,
Strominger JL: Specificity and promiscuity among natu-
rally processed peptides bound to HLA-DR alleles. J Exp
Med 178(1):27, 1993.
32. Marshall KW, Wilson KJ, Liang J, Woods A, Zaller D,
Rothbard JB: Prediction of peptide affinity to HLA
DRB1*0401. J Immunol 154(11):5927, 1995.
33. O’Sullivan D, Sidney J, Appella E, Walker L, Phillips L,
Colon SM, Miles C, Chesnut RW, Sette A: Characteriza-
tion of the specificity of peptide binding to four DR
haplotypes. J Immunol 145(6):1799, 1990.
34. O’Sullivan D, Sidney J, Del Guercio MF, Colon SM, Sette
A: Truncation analysis of several DR binding epitopes.
J Immunol 146(4):1240, 1991.
35. Lasarte JJ, Garcia Granero M, Lopez A, Casares N, Garcia
N, Civeira MP, Borras Cuesta F, Prieto J: Cellular immu-
nity to hepatitis C virus core protein and the response to
interferon in patients with chronic hepatitis C. Hepatol-
ogy 28(3):815, 1998.
36. Merrifield RB: Solid phase peptide synthesis. I. The syn-
thesis of a tetrapeptide. J Am Chem Soc 85:2149, 1963.
37. Atherton E, Logan JC, Sheppard RC: Peptide synthesis II.
Procedures for solid phase synthesis using N-fluorenyl
methoxycarbonyl aminoacids on polyamide supports. Syn-
thesis of substance P and of acyl carrier protein 65-74
decapeptide. J Chem Soc Perkin Trans 1:538, 1989.
38. Borras Cuesta F, Golvano J, Sarobe P, Lasarte JJ, Prieto I,
Szabo A, Guillaume JL, Guillet JG: Insights on the amino
acid side-chain interactions of a synthetic T-cell determi-
nant. Biologicals 19(3):187, 1991.
39. Kaiser E, Colescott RL, Bossinger CD, Cook PI: Color test
for detection of free terminal amino groups in the solid-
phase synthesis of peptides. Anal Biochem 34(2):595,
1970.
40. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z,
Sinigaglia F: Precise prediction of major histocompatibil-
ity complex class II-peptide interaction based on peptide
side chain scanning. J Exp Med 180(6):2353, 1994.
41. Honeyman MC, Brusic V, Stone NL, Harrison LC: Neural
network-based prediction of candidate T-cell epitopes.
Nat Biotechnol 16(10):966, 1998.
42. Southwood S, Sidney J, Kondo A, del Guercio MF, Ap-
pella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM,
Sette A: Several common HLA-DR types share largely
overlapping peptide binding repertoires. J Immunol
160(7):3363, 1998.
43. Sinigaglia F, Guttinger M, Kilgus J, Doran DM, Matile
H, Etlinger H, Trzeciak A, Gillessen D, Pink JR: A
malaria T-cell epitope recognized in association with most
mouse and human MHC class II molecules. Nature
336(6201):778, 1988.
44. Panina Bordignon P, Tan A, Termijtelen A, Demotz S,
Corradin G, Lanzavecchia A: Universally immunogenic T
cell epitopes: promiscuous binding to human MHC class
II and promiscuous recognition by T cells. Eur J Immunol
19(12):2237, 1989.
45. Hickling JK, Fenton CM, Howland K, Marsh SG, Roth-
bard JB: Peptides recognized by class I restricted T cells
also bind to MHC class II molecules. Int Immunol 2(5):
435, 1990.
46. Karr RW, Yu W, Watts R, Evans KS, Celis E: The role
of polymorphic HLA-DR beta chain residues in presenta-
tion of viral antigens to T cells. J Exp Med 172(1):273,
1990.
47. Gyllensten U, Sundvall M, Ezcurra I, Erlich HA: Genetic
diversity at class II DRB loci of the primate MHC.
J Immunol 146(12):4368, 1991.
48. Brown LR, Nygard NR, Graham MB, Bono C, Braciale
VL, Gorka J, Schwartz BD, Braciale TJ: Recognition of
the influenza hemagglutinin by class II MHC-restricted T
lymphocytes and antibodies. I. Site definition and impli-
cations for antigen presentation and T lymphocyte recog-
nition. J Immunol 147(8):2677, 1991.
49. Kilgus J, Jardetzky T, Gorga JC, Trzeciak A, Gillessen D,
Sinigaglia F: Analysis of the permissive association of a
malaria T cell epitope with DR molecules. J Immunol
146(1):307, 1991.
50. Suhrbier A, Rodda SJ, Ho PC, Csurhes P, Dunckley H,
Saul A, Geysen HM, Rzepczyk CM: Role of single amino
acids in the recognition of a T cell epitope. J Immunol
147(8):2507, 1991.
51. Kropshofer H, Max H, Muller CA, Hesse F, Stevanovic S,
Jung G, Kalbacher H: Self-peptide released from class II
HLA-DR1 exhibits a hydrophobic two-residue contact
motif. J Exp Med 175(6):1799, 1992.
52. Harris PE, Liu Z, Suciu-Foca N: MHC class II binding of
peptides derived from HLA-DR 1. J Immunol 148(7):
2169, 1992.
53. Olson RR, De Magistris MT, Di Tommaso A, Karr RW:
Mutations in the third, but not the first or second, hy-
pervariable regions of DR(beta 1*0101) eliminate DR1-
restricted recognition of a pertussis toxin peptide. J Im-
munol 148(9):2703, 1992.
277Peptide Binding to HLA-DR Molecules
54. Newcomb JR, Cresswell P: Characterization of endoge-
nous peptides bound to purified HLA-DR molecules and
their absence from invariant chain-associated alpha beta
dimers. J Immunol 150(2):499, 1993.
55. Chaye H, Ou D, Chong P, Gillam S: Human T- and
B-cell epitopes of E1 glycoprotein of rubella virus. J Clin
Immunol 13(2):93, 1993.
56. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S,
Corradin G, Lanzavecchia A: Universally immunogenic T
cell epitopes: promiscuous binding to human MHC class
II and promiscuous recognition by T cells. Eur J Immunol
19(12):2237, 1989.
57. Feller DC, de la Cruz VF: Identifying antigenic T-cell
sites. Nature 349(6311):720, 1991.
58. Rothbard JB, Gefter ML: Interactions between immuno-
genic peptides and MHC proteins. Annu Rev Immunol
9:527, 1991.
59. Jensen PE: Enhanced binding of peptide antigen to puri-
fied class II major histocompatibility glycoproteins at
acidic pH. J Exp Med 174(5):1111, 1991.
60. Zeliszewski D, Golvano JJ, Gaudebout P, Dorval I, Frei-
del C, Gebuhrer L, Betuel H, Borras Cuesta F, Sterkers G:
Implication of HLA-DR residues at positions 67, 71, and
86 in interaction between HLA-DR11 and peptide
HA306-320. J Immunol 151(11):6237, 1993.
61. Boehncke WH, Takeshita T, Pendleton CD, Houghten
RA, Sadegh Nasseri S, Racioppi L, Berzofsky JA, Germain
RN: The importance of dominant negative effects of
amino acid side chain substitution in peptide-MHC mol-
ecule interactions and T cell recognition. J Immunol
150(2):331, 1993.
62. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG,
Strominger JL, Wiley DC: Crystal structure of the human
class II MHC protein HLA-DR1 complexed with an in-
fluenza virus peptide. Nature 368(6468):215, 1994.
63. Chou PY, Fasman GD: Empirical predictions of protein
conformation. Annu Rev Biochem 47:251, 1978.
64. Garnier J, Osguthorpe DJ, Robson B: Analysis of the
accuracy and implications of simple methods for predict-
ing the secondary structure of globular proteins. J Mol
Biol 120(1):97, 1978.
278 F. Borra´s-Cuesta et al.
